Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

DS, Ernst; IF, Tannock; EW, Winquist; PM, Venner; L, Reyno; MJ, Moore; K, Chi; K, Ding; C, Elliott; W, Parulekar

doi:10.1200/jco.2003.03.042

Public

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

Shared by NobleBlocks on Sep 1, 2003 • 12:00 AM UTC

Authors:

Ernst DS

Tannock IF

Winquist EW

Abstract

Purpose To compare the incidence of palliative response in patients with hormone-resistant prostate cancer (HRPC) treated with mitoxantrone and prednisone (MP) plus clodronate with that of patients treated with MP plus placebo.Materials and methods Men with HRPC, bone metastases, and bone pain were ...

Discussions